132 related articles for article (PubMed ID: 31938268)
1. Hepatic carcinoma with indolent T-lymphoblastic proliferation (iT-LBP).
Kong M; Wang Z; Teng X; Xu L; Liu J; Jiang C; Teng L
Int J Clin Exp Pathol; 2018; 11(3):1674-1678. PubMed ID: 31938268
[TBL] [Abstract][Full Text] [Related]
2. Indolent T-lymphoblastic proliferation involving hepatocellular carcinoma-presentation in novel settings and comprehensive review of literature.
Ghezavati A; Liang CA; Mais D; Nazarullah A
J Hematop; 2023 Sep; 16(3):167-175. PubMed ID: 38175402
[TBL] [Abstract][Full Text] [Related]
3. Indolent T-lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review.
Yasuda H; Tsutsui M; Ota Y; Tanaka M; Komatsu N
Histopathology; 2018 Apr; 72(5):862-866. PubMed ID: 29143359
[TBL] [Abstract][Full Text] [Related]
4. Indolent T-lymphoblastic proliferation associated with Castleman disease and low grade follicular dendric cell sarcoma: report of a case and review of literature.
Chen J; Feng J; Xiao H; Ma Q; Chen Z
Int J Clin Exp Pathol; 2019; 12(4):1497-1505. PubMed ID: 31933967
[TBL] [Abstract][Full Text] [Related]
5. Indolent T-lymphoblastic proliferation with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma: a case report.
Han W; Wang B; Yong X; Zhang Y; Shao M; Wang C
Pathol Oncol Res; 2023; 29():1611151. PubMed ID: 37252318
[No Abstract] [Full Text] [Related]
6. Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma.
Ohgami RS; Arber DA; Zehnder JL; Natkunam Y; Warnke RA
Adv Anat Pathol; 2013 May; 20(3):137-40. PubMed ID: 23574769
[TBL] [Abstract][Full Text] [Related]
7. Exuberant cortical thymocyte proliferation mimicking T-lymphoblastic lymphoma within recurrent large inguinal lymph node masses of localized Castleman disease.
Kansal R; Nathwani BN; Yiakoumis X; Moschogiannis M; Sachanas S; Stefanaki K; Pangalis GA
Hum Pathol; 2015 Jul; 46(7):1057-61. PubMed ID: 25953658
[TBL] [Abstract][Full Text] [Related]
8. sTRBC1 and cyTRBC1 Expression Distinguishes Indolent T-Lymphoblastic Proliferations From T-Lymphoblastic Leukemia/Lymphoma.
Liu J; Li M; Fu J; Dong M; Fan X; Zhong L; Xu G; Li Y; Xi Q
Am J Surg Pathol; 2023 Nov; 47(11):1325-1331. PubMed ID: 37515427
[TBL] [Abstract][Full Text] [Related]
9. Indolent T-lymphoblastic proliferation: A systematic review of the literature analyzing the epidemiologic, clinical, and pathologic features of 45 cases.
Saglam A; Singh K; Gollapudi S; Kumar J; Brar N; Butzmann A; Warnke R; Ohgami RS
Int J Lab Hematol; 2022 Aug; 44(4):700-711. PubMed ID: 35577551
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma with immature T-cell (T-lymphoblastic) proliferation.
Eun S; Jeon YK; Jang JJ
J Korean Med Sci; 2010 Feb; 25(2):309-12. PubMed ID: 20119589
[TBL] [Abstract][Full Text] [Related]
11. Indolent T-lymphoblastic proliferation: a report of three cases.
Yuanyuan Z; Jianlan X; Yanlin Z; Xiaoge Z
Virchows Arch; 2022 May; 480(5):1121-1126. PubMed ID: 34482472
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic features of systemic EBV-positive T/NK-cell lymphoproliferative disease in adults].
Zheng XD; Zhou XG; Jin Y; Xie JL; Wei XJ; Chen SY; Mei X; Gong LP; Lü BB
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):227-34. PubMed ID: 21615995
[TBL] [Abstract][Full Text] [Related]
13. [Indolent T-lymphoblastic proliferation in association with localized Castleman disease: A case report].
Chauveau B; Le Loarer F; Bacci J; Baylac F; Dubus P; Ling C; Parrens M
Ann Pathol; 2019 Feb; 39(1):29-35. PubMed ID: 30554835
[TBL] [Abstract][Full Text] [Related]
14. Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome.
Walters M; Pittelkow MR; Hasserjian RP; Harris NL; Macon WR; Kurtin PJ; Rech KLG
Am J Surg Pathol; 2018 Dec; 42(12):1647-1652. PubMed ID: 30222603
[TBL] [Abstract][Full Text] [Related]
15. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma.
Ohgami RS; Zhao S; Ohgami JK; Leavitt MO; Zehnder JL; West RB; Arber DA; Natkunam Y; Warnke RA
Am J Surg Pathol; 2012 Nov; 36(11):1619-28. PubMed ID: 23060347
[TBL] [Abstract][Full Text] [Related]
16. Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression.
Ohgami RS; Sendamarai AK; Atwater SK; Liedtke M; Fleming MD; Natkunam Y; Warnke RA
Am J Surg Pathol; 2014 Sep; 38(9):1298-304. PubMed ID: 24618611
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological features of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: a report of five cases].
Shao SH; Gu HY; Lin DL; Shi HL; Zhang YJ; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):762-766. PubMed ID: 31594039
[No Abstract] [Full Text] [Related]
18. [Clinicopathologic features of systemic EBV-positive T-cell lymphoproliferative disease of childhood].
Jin Y; Zhou XG; He LJ; Xie JL; Zheng YY; Zhang YN; Zhang SH
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):600-8. PubMed ID: 20079188
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for the Treatment of Airway Obstruction due to Indolent T-Lymphoblastic Proliferation.
Moughames E; Kiess AP; Akst LM; Azar A
Case Reports Immunol; 2019; 2019():1724083. PubMed ID: 31976096
[TBL] [Abstract][Full Text] [Related]
20. Indolent T-lymphoblastic proliferation: report of a case with a 16-year course without cytotoxic therapy.
Velankar MM; Nathwani BN; Schlutz MJ; Bain LA; Arber DA; Slovak ML; Weiss LM
Am J Surg Pathol; 1999 Aug; 23(8):977-81. PubMed ID: 10435569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
